Calcifications on mammo could identify women at risk of CVD
Detecting breast arterial calcifications on routine mammograms could identify women at a higher risk of future cardiovascular disease (CVD), a study published March 13 in Clinical Imaging found. Researchers led by Shadi Azam, PhD, from Weill Cornell Medicine in New York found links between such calcifications and older age, diabetes, parity, younger age at first birth, and hypertension in women who underwent both screening mammography and cardiac CT angiography (CCTA). “Additionally, we found that when neither breast arterial calcifications nor coronary arterial calcifications were present, the estimated 10-year risk o...
Source: AuntMinnie.com Headlines - March 15, 2024 Category: Radiology Authors: Amerigo Allegretto Tags: Womens Imaging Source Type: news

Eliminating Medicaid dental benefits and early-stage oral cancer diagnoses
ConclusionsEliminating Medicaid dental benefits negatively impacted early detection of cancers of the oral cavity. Continued volatility of Medicaid dental coverage and provider shortages may be further delaying oral cancer diagnoses. Alternative approaches are needed to prevent advanced stage OPC. (Source: Dental Technology Blog)
Source: Dental Technology Blog - March 13, 2024 Category: Dentistry Source Type: news

Beta-defensin index: A functional biomarker for oral cancer detection
 Cell Reports Mediine AccessPublished:March 04, 2024DOI:https://doi.org/10.1016/j.xcrm.2024.101447SummaryThere is an unmet clinical need for a non-invasive and cost-effective test for oral squamous cell carcinoma (OSCC) that informs clinicians when a biopsy is warranted. Human beta-defensin 3 (hBD-3), an epithelial cell-derived anti-microbial peptide, is pro-tumorigenic and overexpressed in early-stage OSCC compared to hBD-2. We validate this expression dichotomy in carcinoma in situ and OSCC lesions using immunofluorescence microscopy and flow cytometry. The proportion of hBD-3/hBD-2 levels in non-invasivel...
Source: Dental Technology Blog - March 12, 2024 Category: Dentistry Source Type: news

Drug Discount May Boost Adherence to Prostate Cancer Therapy Drug Discount May Boost Adherence to Prostate Cancer Therapy
The 340B drug discount program was not associated with oral specialty drug use in advanced prostate cancer but was linked to better adherence to medication in more vulnerable patients.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 11, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

Quality of life of patients treated with robotic surgery in the oral and maxillofacial region: a scoping review of empirical evidence
ConclusionCompared to the conventional treatment modalities, TORS has demonstrated better QoL, mostly in the domains related to oral functions such as swallowing and speech, among patients treated with such. This improvement was most evident within the initial post-operative year. (Source: Dental Technology Blog)
Source: Dental Technology Blog - March 7, 2024 Category: Dentistry Source Type: news

Scientists Develop Biopsy-Free Means of Spotting Oral Cancers
TUESDAY, March 5, 2024 -- Analysis of a " chemical score " from mouth lesion swab samples might allow patients to skip painful biopsies, getting oral cancers promptly diagnosed in a noninvasive way, scientists report. Right now, dentists and other... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 5, 2024 Category: General Medicine Source Type: news

Novel Therapy Promising for Radiation-Induced Oral Mucositis
(MedPage Today) -- The first-in-class uridine phosphorylase inhibitor TK-90 almost completely eliminated severe oral mucositis (SOM) in patients with non-metastatic squamous cell carcinoma of the head and neck who underwent radiation therapy, a... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 5, 2024 Category: Hematology Source Type: news

The First Over-the-Counter Birth Control Pill Is Here
The first birth control pill that people can buy without a prescription, called Opill, is shipping to stores this week. Perrigo, the Ireland-based company that makes Opill, said the pills should be available to purchase at retail pharmacies and online by the end of March. The pills are designed to be taken daily at about the same time each day, and they will be sold in one-month packs for $19.99 and three-month packs for $49.99. [time-brightcove not-tgx=”true”] A spokesperson for CVS, one pharmacy that will be stocking the pill, said the pills will be in more than 7,500 of its stores nationwide and will ...
Source: TIME: Health - March 4, 2024 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthscienceclimate Source Type: news

Zyn Is the New Vaping
Not so long ago, Juul was seen as the new Marlboro. Smoking wasn’t that cool anymore—rates had plummeted among U.S. adults and teens—but then came Juul, a sleek, addictive product with flashy advertising tactics that took off like wildfire. It soon became clear that e-cigarettes were hooking teens who otherwise wouldn’t have gone near nicotine. [time-brightcove not-tgx=”true”] Now, Juul is out and Zyn is in. It’s even more discreet than Juul, with no plumes of vapor. A user simply tucks a small pouch of nicotine, additives, and flavorings under their lip for up to an hour. Over...
Source: TIME: Health - March 4, 2024 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized healthscienceclimate Source Type: news

Lunit to present studies at ECR 2024
Lunit will highlight four oral presentations and three poster presentations at ECR 2024, ranging from adaptability in different use cases to the potential to act as an independent reader in mammography double-reading settings. Oral presentations featuring Lunit INSIGHT at ECR 2024 include the following: ul.editorialList li {margin-bottom:6px;} “The performance of a commercial artificial intelligence algorithm in an external quality assurance scheme regularly used by humans in the NHS breast screening programme” (ACV 2024 Research Stage 2, February 28, 3 p.m. to 4 p.m.) “The Multi- Sixteen Thousand and Counting:...
Source: AuntMinnie.com Headlines - February 28, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news

Enobosarm Has Antitumor Activity in ER-Positive, HER2-Negative Advanced Breast Cancer
TUESDAY, Feb. 27, 2024 -- The oral selective androgen receptor modulator enobosarm has antitumor activity and can yield clinical benefit in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 27, 2024 Category: Pharmaceuticals Source Type: news

Bayer receives U.S. FDA Breakthrough Therapy designation for BAY 2927088 for non-small cell lung cancer harboring HER2 activating mutations
Bayer announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for BAY 2927088 for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, and who have received a prior systemic therapy. BAY 2927088 is an oral, reversible tyrosine kinase inhibitor (TKI) that potently inhibits mutant human epidermal growth factor receptors 2 (HER2), (Source: World Pharma News)
Source: World Pharma News - February 27, 2024 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news

Gadget that shines bright red LEDs to mend cancer scars now being used to treat debilitating scarring and swelling in the mouth caused by radiotherapy
The therapy - known as photobiomodulation - is being offered to NHS patients in Nottingham, where experts claim it has proved remarkably successful. (Source: the Mail online | Health)
Source: the Mail online | Health - February 25, 2024 Category: Consumer Health News Source Type: news

New cancer therapy approved by FDA supercharges body ’s immune system
After undergoing surgery, radiation and three different therapies, Scott Goedeke faced a tough reality: The cancer that first surfaced on the roof of his mouth had spread to a lymph node in his neck. So the 58-year-old health-care consultant agreed to an experimental treatment that would deploy…#scottgoedeke #sitemancancercenter #stlouis #fda #steverosenberg #iovance #frederickvogt #jasonbock #ctmc (Source: Reuters: Health)
Source: Reuters: Health - February 21, 2024 Category: Consumer Health News Source Type: news

Do we recognize oral cancer? Primary professional delay in diagnosis of oral squamous cell carcinoma
ConclusionsOSCC patients seek care actively. Primary professional delay affects the care of every tenth OSCC patient.Clinical relevanceThe role of health care professionals is essential for early OSCC diagnosis, especially in urgent care. Clinicians ’ knowledge of the typical symptoms and findings of OSCC should be improved. (Source: Dental Technology Blog)
Source: Dental Technology Blog - February 14, 2024 Category: Dentistry Source Type: news